Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Ratios

Lyra Therapeutics (LYRA) Asset Writedowns and Impairment (2023 - 2024)

Lyra Therapeutics has reported Asset Writedowns and Impairment over the past 2 years, most recently at $1.8 million for Q4 2024.

Quarterly results put Asset Writedowns and Impairment at $1.8 million for Q4 2024, up 21900.0% from a year ago — trailing twelve months through Sep 2025 was $1.8 million (down 6.93% YoY), and the annual figure for FY2024 was $1.9 million, up 18.75%.
Asset Writedowns and Impairment for Q4 2024 was $1.8 million at Lyra Therapeutics, down from $1.9 million in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for LYRA hit a ceiling of $1.9 million in Q2 2024 and a floor of $8000.0 in Q4 2023.